AN2 Therapeutics
ANTX
37 hedge funds and large institutions have $320M invested in AN2 Therapeutics in 2023 Q3 according to their latest regulatory filings, with 14 funds opening new positions, 12 increasing their positions, 8 reducing their positions, and 8 closing their positions.
221% more capital invested
Capital invested by funds: $99.9M → $320M (+$220M)
75% more first-time investments, than exits
New positions opened: 14 | Existing positions closed: 8
50% more repeat investments, than reductions
Existing positions increased: 12 | Existing positions reduced: 8
19% more funds holding
Funds holding: 31 → 37 (+6)
6.66% more ownership
Funds ownership: 60.43% → 67.09% (+6.7%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RCM
RA Capital Management
Boston,
Massachusetts
|
+$20.1M |
| 2 |
FLSM
Frazier Life Sciences Management
Palo Alto,
California
|
+$15.7M |
| 3 |
TCM
TCG Crossover Management
Palo Alto,
California
|
+$15.7M |
| 4 |
Adage Capital Partners
Boston,
Massachusetts
|
+$10.3M |
| 5 |
Marshall Wace
London,
United Kingdom
|
+$8.12M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
MIM
Monashee Investment Management
Boston,
Massachusetts
|
-$934K |
| 2 |
PAG
Private Advisor Group
Morristown,
New Jersey
|
-$574K |
| 3 |
Alyeska Investment Group
Chicago,
Illinois
|
-$548K |
| 4 |
Morgan Stanley
New York
|
-$447K |
| 5 |
Goldman Sachs
New York
|
-$332K |
ANTX Hedge Fund Activity: Q3 2023 in Review
37 of the 6,301 institutional investors tracked by Wall St. Rank reported a position in AN2 Therapeutics (ANTX) for Q3 2023, worth a combined $320M — up 221% from $99.9M a quarter earlier.
Buyers outnumbered sellers: 14 funds opened new ANTX positions and 8 closed out — a net gain of 6 holders — while 12 added to existing stakes and 8 trimmed.
The largest buyer was RA Capital Management, adding an estimated $20.1M. The largest seller was Monashee Investment Management, cutting an estimated $934K.
- 37 institutional investors held AN2 Therapeutics (ANTX) as of Q3 2023, up from 31 in Q2 2023.
- Funds reported $320M of AN2 Therapeutics stock for Q3 2023, up 221% quarter-over-quarter.
- 14 funds opened new AN2 Therapeutics positions in Q3 2023 and 8 closed out, a net change of +6 holders.
- The largest AN2 Therapeutics buyer in Q3 2023 was RA Capital Management, an estimated $20.1M added.
- The largest AN2 Therapeutics seller in Q3 2023 was Monashee Investment Management, an estimated $934K sold.
Based on aggregated 13F filings for Q3 2023.